Literature DB >> 30426327

Annual Congress of the European Society for Medical Oncology (ESMO): Munich, Germany, 19-23 October 2018.

Martin Chopra1.   

Abstract

Year:  2018        PMID: 30426327     DOI: 10.1007/s11523-018-0608-8

Source DB:  PubMed          Journal:  Target Oncol        ISSN: 1776-2596            Impact factor:   4.493


× No keyword cloud information.
  14 in total

1.  Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

Authors:  Jennifer K Litton; Hope S Rugo; Johannes Ettl; Sara A Hurvitz; Anthony Gonçalves; Kyung-Hun Lee; Louis Fehrenbacher; Rinat Yerushalmi; Lida A Mina; Miguel Martin; Henri Roché; Young-Hyuck Im; Ruben G W Quek; Denka Markova; Iulia C Tudor; Alison L Hannah; Wolfgang Eiermann; Joanne L Blum
Journal:  N Engl J Med       Date:  2018-08-15       Impact factor: 91.245

2.  Immune Checkpoint Blockade: The New Frontier in Cancer Treatment.

Authors:  Jeffrey M Clarke; Daniel J George; Stacey Lisi; April K S Salama
Journal:  Target Oncol       Date:  2018-02       Impact factor: 4.493

Review 3.  Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer.

Authors:  Rekha A Kumbla; Robert A Figlin; Edwin M Posadas
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

Review 4.  Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.

Authors:  Carsten Denkert; Cornelia Liedtke; Andrew Tutt; Gunter von Minckwitz
Journal:  Lancet       Date:  2016-12-07       Impact factor: 79.321

Review 5.  Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.

Authors:  Smruthi Vijayaraghavan; Stacy Moulder; Khandan Keyomarsi; Rachel M Layman
Journal:  Target Oncol       Date:  2018-02       Impact factor: 4.493

6.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Authors:  Kathleen Moore; Nicoletta Colombo; Giovanni Scambia; Byoung-Gie Kim; Ana Oaknin; Michael Friedlander; Alla Lisyanskaya; Anne Floquet; Alexandra Leary; Gabe S Sonke; Charlie Gourley; Susana Banerjee; Amit Oza; Antonio González-Martín; Carol Aghajanian; William Bradley; Cara Mathews; Joyce Liu; Elizabeth S Lowe; Ralph Bloomfield; Paul DiSilvestro
Journal:  N Engl J Med       Date:  2018-10-21       Impact factor: 91.245

7.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

8.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

Authors:  Mark Robson; Seock-Ah Im; Elżbieta Senkus; Binghe Xu; Susan M Domchek; Norikazu Masuda; Suzette Delaloge; Wei Li; Nadine Tung; Anne Armstrong; Wenting Wu; Carsten Goessl; Sarah Runswick; Pierfranco Conte
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245

Review 9.  Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.

Authors:  Ronan Flippot; Bernard Escudier; Laurence Albiges
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

Review 10.  PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.

Authors:  Geraldine O'Sullivan Coyne; Alice P Chen; Robert Meehan; James H Doroshow
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

View more
  1 in total

Review 1.  Clinical Trials of Oncolytic Viruses in Breast Cancer.

Authors:  Mary E Carter; André Koch; Ulrich M Lauer; Andreas D Hartkopf
Journal:  Front Oncol       Date:  2021-12-23       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.